Neurogene Inc. (NGNE)

NASDAQ • Healthcare

$23.55

-$0.73 (-3.0%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$24.11

Day Range$23.08 - $24.11

Avg. Volume (3M)320.2K

Market Cap$372.1M

52 Week Range

$15.93$43.66

Next EarningsIn 18 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$111.1M

EPS (TTM)

-$5.51

ROA (TTM)

-45.47%

Current Ratio

10.64

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+8.7%Q3 2025-$1.05

+21.4%Q4 2025-$0.99

+9.6%Q1 2026-$1.12

-7.2%Q2 2026-$1.39

-7.7%Q3 2026-$1.53

Nov 12

in 18 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -7.7%

Neurogene trailed consensus on EPS in the second fiscal quarter of 2026, based on preliminary results reported August 11, 2026, with EPS of -$1.53 trailing the -$1.42 estimate by -$0.11 and down from -$1.05 a year ago (-45.7% YoY). The clinical-stage gene therapy developer posted a GAAP net loss of roughly $34.5 million, versus a net loss of about $22.0 million a year ago (-56.6% YoY), alongside an operating loss of around $36.7 million as it continued advancing its pipeline programs, including NGN-401 and NGN-101. Cash burn remained evident, with operating cash flow of about -$23.8 million for the quarter. For the next period, consensus calls for EPS of -$1.39.

Next report — what to expect

Neurogene Inc. (NGNE) reports next on November 12, 2026. The Street is looking for consensus EPS of -$1.49. Historically, Neurogene has beaten EPS in 5 of 8 most recent quarters, making EPS versus expectations a key focus going into the print.

View full earnings history

About Neurogene Inc.

Neurogene Inc. is a NASDAQ-listed Biotechnology company in healthcare that develops genetic medicines for neurological conditions. The company remains a clinical-stage business rather than a commercial drug seller, and its work centers on rare neurologic disorders through a focused pipeline built around gene therapy candidates.

Name

Neurogene Inc.

CEO

Rachel L. McMinn

Website

www.neurogene.com

Industry

Healthcare

Employees

131

Today's Snapshot

AI-generated

The day ended with NGNE 3% lower at 23.55, in line with a weaker sector. Trading was lighter than usual, with volume about a third of its usual level.

Trading Volume

Below 10d avg (388.3K)

124.5K

vs S&P 500 Today

Underperforming Market

-2.49%

Updated: October 23, 2026 at 20:15 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

NGNE looks technically weak with the market price about $23.55 and momentum skewed downward: RSI below neutral and momentum measures negative, while MACD is non-positive. The issue is compounded by the stock trading below most moving averages, including the 200-day, which signals broad-term weakness. ADX near the low 20s suggests only modest trend strength, but ATR is relatively high at roughly 8.8%, indicating larger moves on downside pressure; on-balance volume shows pockets of accumulation but does not offset the bias. Technical takeaway: Strong Sell.

All signals